Episode 32: 2025 breakthroughs in VTE and AF

About this episode

Dr Behnood Bikdeli joins Dr Barnes to discuss major advances in VTE and AF management in 2025.

“I am sure 2026 is going to be even more exciting.” Dr Behnood Bikdeli joins Dr Barnes to discuss major advances in VTE and AF management in 2025, including the impact of trials such as API-CAT, RENOVE, and HI-PRO in VTE, and AMAFI, OPTION, and ADAPT-DES in AF. Highlights include the shift towards treatment personalisation and a “less is more” approach in clinical practice.

People in this episode

Host: Dr Barnes

Guest: Dr Behnood Bikdeli

Topics covered

• VTE management
• AF management
• treatment personalisation
• clinical practice
• medical trials
• 2025 breakthroughs

Keywords

• VTE
• AF
• treatment personalisation
• clinical trials
• API-CAT
• RENOVE
• HI-PRO
• AMAFI
• OPTION
• ADAPT-DES

Mentioned in this episode

Organizations: API-CAT, RENOVE, HI-PRO, AMAFI, OPTION, ADAPT-DES

More episodes of Thrombosis in conversation

• Episode 33: The emotional toll of VTE: A patient’s perspective · December 4, 2025 · 25 min
• Episode 31: Optimising treatment duration for thrombosis · October 10, 2025 · 26 min
• Episode 30: VTE and AF at ESC 2025 · September 10, 2025 · 36 min
• Episode 29: Individualised care in special populations · March 18, 2025 · 20 min
• Episode 28: Real-world evidence: Addressing gaps in VTE and AF clinical research · March 6, 2025 · 20 min
• Episode 27: A multidisciplinary approach to CAT · February 18, 2025 · 15 min